https://m2.mtmt.hu/ hun 2026-09-22 06:45 JournalArticle 34740343 VALIDATED true 0 false 2026-06-10T12:37:31.818+0000 2024-06-07T09:41:13.226+0000 2024-03-14T13:20:23.729+0000 true 10003491 Gonda Xénia /api/author/10003491 Author Gonda Xénia (Pszichiátria, pszichiátriai genetika, farmakológia, pszichofarmakológia, pszichoterápia, klinikai pszichológia, pszichológia) true 10003491 2024-08-16T09:16:50.881+0000 2024-08-16T09:16:50.881+0000 2024-04-03T08:21:47.911+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Gonda, Xenia true true /api/journal/1528 REVIEWED EUROPEAN NEUROPSYCHOPHARMACOLOGY 0924-977X 1873-7862 true false 1528 false 1528 true 0924-977X 1873-7862 Journal FOREIGN 83 1 8 1 8 2024 true true 2024 true true true false true false NONE 2026-06-10 false 4 0 4 4 0 4 4 4 3 4 4 4 4 4 0 0 4 4 4 4 0 2 2 Folyóiratcikk Journal Article 24 4 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 2 2 2 2 2026 0 2 2 2 2 D1 false false false false 2024-04-02T08:21:47.576+0000 NAP3.0-SE Neuropszichofarmakológiai Kutatócsoport (SE / GYTK / GYHATAS); Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K) 4 32 2 4 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 115827877 /api/authorship/115827877 Gonda, Xenia ✉ [Gonda, Xénia (Pszichiátria, psz...), szerző] Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K); NAP3.0-SE Neuropszichofarmakológiai Kutatócsoport (SE / GYTK / GYHATAS) 1 0.25 true false true Author 10003491 /api/author/10003491 Gonda Xénia (Pszichiátria, pszichiátriai genetika, farmakológia, pszichofarmakológia, pszichoterápia, klinikai pszichológia, pszichológia) Gonda Xénia true 10003491 true Gonda Xenia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115827878 /api/authorship/115827878 Balint, Sara [Bálint, Sára (Pszichiátria), szerző] Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K) 2 0.25 false false false Author 10043365 /api/author/10043365 Bálint Sára (Pszichiátria) Bálint Sára true 10043365 true Balint Sara true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115827879 /api/authorship/115827879 Rethelyi, Janos Miklos [Réthelyi, János (Pszichiátria- kog...), szerző] Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K) 3 0.25 false false false Author 10021998 /api/author/10021998 Réthelyi János (Pszichiátria- kognítiv idegtudomány) Réthelyi János true 10021998 true Rethelyi Janos Miklos true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 115827880 /api/authorship/115827880 Dome, Peter [Döme, Péter (pszichiátria), szerző] Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K) 4 0.25 false true false Author 10023468 /api/author/10023468 Döme Péter (pszichiátria) Döme Péter true 10023468 true Dome Peter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 25872585 /api/publicationidentifier/25872585 DOI: 10.1016/j.euroneuro.2024.03.002 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1016/j.euroneuro.2024.03.002 https://doi.org/10.1016/j.euroneuro.2024.03.002 false true PublicationIdentifier 26416889 /api/publicationidentifier/26416889 WoS: 001225869700001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001225869700001 https://www.webofscience.com/wos/woscc/full-record/001225869700001 true true PublicationIdentifier 25934645 /api/publicationidentifier/25934645 Scopus: 85188087977 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85188087977 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85188087977 true true PublicationIdentifier 25934653 /api/publicationidentifier/25934653 PubMed: 38490015 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38490015 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38490015&dopt=Abstract true true SjrRating 11487041 /api/sjrrating/11487041 sjr:D1 (2024) Scopus - Neurology (clinical) EUROPEAN NEUROPSYCHOPHARMACOLOGY 0924-977X 1873-7862 38 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2728 /api/classificationexternal/2728 Scopus - Neurology (clinical) true 2728 true D1 DIRECT true true Reference 51049178 /api/reference/51049178 1. Abdelnour 2022: ADHD diagnostic trends: increased recognition or overdiagnosis?., Mo Med., 119, p. 467 1 false true Reference 51049179 /api/reference/51049179 2. Adamis 2022: ADHD in adults: a systematic review and meta-analysis of prevalence studies in outpatient psychiatric clinics., J. Atten. Disord., 26, p. 1523, DOI: 10.1177/10870547221085503 2 10.1177/10870547221085503 false true Reference 51049180 /api/reference/51049180 3. Altabella 2014: MR imaging-detectable metabolic alterations in attention deficit/hyperactivity disorder: from preclinical to clinical studies., AJNR Am. J. Neuroradiol., 35, p. S55, DOI: 10.3174/ajnr.A3843 3 10.3174/ajnr.A3843 false true Reference 51049181 /api/reference/51049181 4. Antshel 2020: Attention deficit hyperactivity disorder., Handb. Clin. Neurol., 174, p. 37, DOI: 10.1016/B978-0-444-64148-9.00003-X 4 10.1016/B978-0-444-64148-9.00003-X false true Reference 51049182 /api/reference/51049182 5. Bai 2020: Acceptance and commitment therapy (ACT) to reduce depression: a systematic review and meta-analysis., J Affect Disorders, 260, p. 728, DOI: 10.1016/j.jad.2019.09.040 5 10.1016/j.jad.2019.09.040 false true Reference 51049183 /api/reference/51049183 6. Boland 2020: A literature review and meta-analysis on the effects of ADHD medications on functional outcomes., J. Psychiatr. Res., 123, p. 21, DOI: 10.1016/j.jpsychires.2020.01.006 6 10.1016/j.jpsychires.2020.01.006 false true Reference 51049184 /api/reference/51049184 7. Boyer 2015: Two novel CBTs for adolescents with ADHD: the value of planning skills., Eur. Child Adolesc. Psychiatry, 24, p. 1075, DOI: 10.1007/s00787-014-0661-5 7 10.1007/s00787-014-0661-5 false true Reference 51049185 /api/reference/51049185 8. Byrne 2021: A systematic review of the use of acceptance and commitment therapy in supporting parents., Psychol. Psychother.: Theory Res. Practice, 94, p. 378, DOI: 10.1111/papt.12282 8 10.1111/papt.12282 false true Reference 51049186 /api/reference/51049186 9. Champ 2021: The impact of psychological theory on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults: a scoping review., PLoS One, 16, DOI: 10.1371/journal.pone.0261247 9 10.1371/journal.pone.0261247 false true Reference 51049187 /api/reference/51049187 10. Coghill 2021: The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)., Eur. Child Adolesc. Psychiatry, p. 1 10 false true Reference 51049188 /api/reference/51049188 11. Conway 2012: Psychodynamic psychotherapy of ADHD: a review of the literature., Psychotherapy, 49, p. 404, DOI: 10.1037/a0027344 11 10.1037/a0027344 false true Reference 51049189 /api/reference/51049189 12. Corser 2023: 0585 A four-week randomized, double-blind, placebo-controlled, phase 2 study of mazindol ER in the treatment of narcolepsy., Sleep, 46, p. A257, DOI: 10.1093/sleep/zsad077.0585 12 10.1093/sleep/zsad077.0585 false true Reference 51049190 /api/reference/51049190 13. Evans 2018: Systematic review of meditation-based interventions for children with ADHD., Eur. Child Adolesc. Psychiatry, 27, p. 9, DOI: 10.1007/s00787-017-1008-9 13 10.1007/s00787-017-1008-9 false true Reference 51049191 /api/reference/51049191 14. Evans 2016: Evaluation of a school-based treatment program for young adolescents with ADHD., J. Consult. Clin. Psychol., 84, p. 15, DOI: 10.1037/ccp0000057 14 10.1037/ccp0000057 false true Reference 51049192 /api/reference/51049192 15. Evans 2014: Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder., J. Clin. Child Adolesc.Psychol., 43, p. 527, DOI: 10.1080/15374416.2013.850700 15 10.1080/15374416.2013.850700 false true Reference 51049193 /api/reference/51049193 16. Evans 2011: Effectiveness of the challenging horizons after-school program for young adolescents with ADHD., Behav. Ther., 42, p. 462, DOI: 10.1016/j.beth.2010.11.008 16 10.1016/j.beth.2010.11.008 false true Reference 51049194 /api/reference/51049194 17. Faraone 2018: The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities., Neurosc. Biobehav. Rev., 87, p. 255, DOI: 10.1016/j.neubiorev.2018.02.001 17 10.1016/j.neubiorev.2018.02.001 false true Reference 51049195 /api/reference/51049195 18. Faraone 2021: The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder., Neurosci. Biobehav.Rev., 128, p. 789, DOI: 10.1016/j.neubiorev.2021.01.022 18 10.1016/j.neubiorev.2021.01.022 false true Reference 51049196 /api/reference/51049196 19. Faraone 2021: The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder., Neurosci. Biobehav. Rev., 128, p. 789, DOI: 10.1016/j.neubiorev.2021.01.022 19 10.1016/j.neubiorev.2021.01.022 false true Reference 51049197 /api/reference/51049197 20. FDA, 2023. Treating and dealing with ADHD (retrieved 26/2/2024). https://www.fda.gov/consumers/consumer-updates/treating-and-dealing-adhd. 20 false true Reference 51049198 /api/reference/51049198 21. Fullen 2020: Psychological treatments in adult ADHD: a systematic review., J. Psychopathol. Behav. Assess., 42, p. 500, DOI: 10.1007/s10862-020-09794-8 21 10.1007/s10862-020-09794-8 false true Reference 51049199 /api/reference/51049199 22. Galvez-Contreras 2022: Therapeutic approaches for ADHD by developmental stage and clinical presentation., Int. J. Environ. Res. Public Health, 19, DOI: 10.3390/ijerph191912880 22 10.3390/ijerph191912880 false true Reference 51049200 /api/reference/51049200 23. 2022: Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019., Lancet Psychiatry, 9, p. 137, DOI: 10.1016/S2215-0366(21)00395-3 23 10.1016/S2215-0366(21)00395-3 false true Reference 51049201 /api/reference/51049201 24. Ginsberg 2014: Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature., Prim. Care Companion. CNS Disord., 16, p. 23591 24 false true Reference 51049202 /api/reference/51049202 25. Gjervan 2012: Functional impairment and occupational outcome in adults with ADHD., J. Atten. Disord., 16, p. 544, DOI: 10.1177/1087054711413074 25 10.1177/1087054711413074 false true Reference 51049203 /api/reference/51049203 26. Gupte-Singh 2017: Economic burden of attention-deficit/hyperactivity disorder among pediatric patients in the United States., Value Health, 20, p. 602, DOI: 10.1016/j.jval.2017.01.007 26 10.1016/j.jval.2017.01.007 false true Reference 51049204 /api/reference/51049204 27. Halmoy 2022: Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trial., BMC Psychiatry, 22, p. 738, DOI: 10.1186/s12888-022-04356-6 27 10.1186/s12888-022-04356-6 false true Reference 51049205 /api/reference/51049205 28. Hartung 2022: Proposed terminology to distinguish adult-onset from late-identified ADHD: a preliminary effort in a large survey of adults aged 18 to 80., ADHD Rep., 30, p. 1, DOI: 10.1521/adhd.2022.30.6.1 28 10.1521/adhd.2022.30.6.1 false true Reference 51049206 /api/reference/51049206 29. Haugan 2022: Cognitive behavioural group therapy as addition to psychoeducation and pharmacological treatment for adolescents with ADHD symptoms and related impairments: a randomised controlled trial., BMC Psychiatry, 22, p. 375, DOI: 10.1186/s12888-022-04019-6 29 10.1186/s12888-022-04019-6 false true Reference 51049207 /api/reference/51049207 30. Hayes 2017: The third wave of cognitive behavioral therapy and the rise of process-based care., World Psychiatry, 16, p. 245, DOI: 10.1002/wps.20442 30 10.1002/wps.20442 false true Reference 51049208 /api/reference/51049208 31. Hesslinger 2002: Psychotherapy of attention deficit hyperactivity disorder in adults–a pilot study using a structured skills training program., Eur. Arch. Psychiatry Clin. Neurosci., 252, p. 177, DOI: 10.1007/s00406-002-0379-0 31 10.1007/s00406-002-0379-0 false true Reference 51049209 /api/reference/51049209 32. Hirvikoski 2011: Reduced ADHD symptoms in adults with ADHD after structured skills training group: results from a randomized controlled trial., Behav. Res. Ther., 49, p. 175, DOI: 10.1016/j.brat.2011.01.001 32 10.1016/j.brat.2011.01.001 false true Reference 51049210 /api/reference/51049210 33. Hirvikoski 2015: Cognitive behavior therapy-based psychoeducational groups for adults with ADHD and their significant others (PEGASUS): an open clinical feasibility trial., Atten. Defic. Hyperact. Disord., 7, p. 89, DOI: 10.1007/s12402-014-0141-2 33 10.1007/s12402-014-0141-2 false true Reference 51049211 /api/reference/51049211 34. Jensen 2016: Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses., Atten. Defic. Hyperact. Disord., 8, p. 3, DOI: 10.1007/s12402-016-0188-3 34 10.1007/s12402-016-0188-3 false true Reference 51049212 /api/reference/51049212 35. Katzman 2017: Adult ADHD and comorbid disorders: clinical implications of a dimensional approach., BMC Psychiatry, 17, p. 1, DOI: 10.1186/s12888-017-1463-3 35 10.1186/s12888-017-1463-3 false true Reference 51049213 /api/reference/51049213 36. Kazda 2023: Increased diagnosis of attention-deficit hyperactivity disorder despite stable hyperactive/inattentive behaviours: evidence from two birth cohorts of Australian children., J. Child Psychol. Psychiatry, 64, p. 1140, DOI: 10.1111/jcpp.13700 36 10.1111/jcpp.13700 false true Reference 51049214 /api/reference/51049214 37. Knouse 2014: Cognitive behavioural therapies for ADHD.Attention Deficit Hyperactivity Disorder: A Handbook For Diagnosis and Treatment, p. 757 37 false true Reference 51049215 /api/reference/51049215 38. Krisanaprakornkit 2010: Meditation therapies for attention-deficit/hyperactivity disorder (ADHD)., Cochrane Database Syst. Rev., DOI: 10.1002/14651858.CD006507.pub2 38 10.1002/14651858.CD006507.pub2 false true Reference 51049216 /api/reference/51049216 39. Langberg 2012: Evaluation of the homework, organization, and planning skills (HOPS) intervention for middle school students with attention deficit hyperactivity disorder as implemented by school mental health providers., School Psych. Rev., 41, p. 342, DOI: 10.1080/02796015.2012.12087514 39 10.1080/02796015.2012.12087514 false true Reference 51049217 /api/reference/51049217 40. Langberg 2011: Refinement of an organizational skills intervention for adolescents with ADHD for implementation by school mental health providers., School Ment. Health, 3, p. 143, DOI: 10.1007/s12310-011-9055-8 40 10.1007/s12310-011-9055-8 false true Reference 51049218 /api/reference/51049218 41. Lee 2017: The effectiveness of mindfulness-based intervention in attention on individuals with ADHD: a systematic review., Hong Kong J. Occupat. Ther., 30, p. 33, DOI: 10.1016/j.hkjot.2017.05.001 41 10.1016/j.hkjot.2017.05.001 false true Reference 51049219 /api/reference/51049219 42. Lee 2022: Effects of Mindfulness-based interventions in children and adolescents with ADHD: a systematic review and meta-analysis of randomized controlled trials., Int. J. Environ. Res. Public Health, 19, DOI: 10.3390/ijerph192215198 42 10.3390/ijerph192215198 false true Reference 51049220 /api/reference/51049220 43. Liu 2023: Omega-3 polyunsaturated fatty acids for core symptoms of attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials., J. Clin. Psychiatry, 84, DOI: 10.4088/JCP.22r14772 43 10.4088/JCP.22r14772 false true Reference 51049221 /api/reference/51049221 44. Lopez 2018: Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults., Cochrane Database Syst. Rev., 3 44 false true Reference 51049222 /api/reference/51049222 45. Luoma 2007: Learning ACT: An Acceptance & Commitment Therapy Skills-Training Manual For Therapists 45 false true Reference 51049223 /api/reference/51049223 46. McGough 2017: Adult manifestations of attention-deficit/hyperactivity disorder.Kaplan & Sadock's Comprehensive Textbook of Psychiatry 46 false true Reference 51049224 /api/reference/51049224 47. Mechler 2022: Evidence-based pharmacological treatment options for ADHD in children and adolescents., Pharmacol. Ther., 230, DOI: 10.1016/j.pharmthera.2021.107940 47 10.1016/j.pharmthera.2021.107940 false true Reference 51049225 /api/reference/51049225 48. Munawar 2021: Acceptance and commitment therapy for individuals having attention deficit hyperactivity disorder (ADHD): a scoping review., Heliyon, 7, p. e07842, DOI: 10.1016/j.heliyon.2021.e07842 48 10.1016/j.heliyon.2021.e07842 false true Reference 51049226 /api/reference/51049226 49. Nazarova 2022: Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials., Front. Pharmacol., 13, DOI: 10.3389/fphar.2022.1066988 49 10.3389/fphar.2022.1066988 false true Reference 51049227 /api/reference/51049227 50. 2023: Neurofeedback for attention-deficit/hyperactivity disorder: 25-month follow-up of double-blind randomized controlled trial., J. Am. Acad. Child Adolesc. Psychiatry, 62, p. 435, DOI: 10.1016/j.jaac.2022.07.862 50 10.1016/j.jaac.2022.07.862 false true Reference 51049228 /api/reference/51049228 51. Newcorn 2022: Nonstimulant treatments for ADHD., Child Adolesc. Psychiatr. Clin. N. Am., 31, p. 417, DOI: 10.1016/j.chc.2022.03.005 51 10.1016/j.chc.2022.03.005 false true Reference 51049229 /api/reference/51049229 52. Nimmo-Smith 2020: Non-pharmacological interventions for adult ADHD: a systematic review., Psychol. Med., 50, p. 529, DOI: 10.1017/S0033291720000069 52 10.1017/S0033291720000069 false true Reference 51049230 /api/reference/51049230 53. Oliva 2021: The efficacy of mindfulness-based interventions in attention-deficit/hyperactivity disorder beyond core symptoms: a systematic review, meta-analysis, and meta-regression., J. Affect. Disord., 292, p. 475, DOI: 10.1016/j.jad.2021.05.068 53 10.1016/j.jad.2021.05.068 false true Reference 51049231 /api/reference/51049231 54. Pagán 2023: Adult attention-deficit/hyperactivity disorder: a narrative review of biological mechanisms, treatments, and outcomes., Curr. Neurol. Neurosci. Rep., 23, p. 451, DOI: 10.1007/s11910-023-01280-4 54 10.1007/s11910-023-01280-4 false true Reference 51049232 /api/reference/51049232 55. Pahnke 2019: Acceptance and commitment therapy for autistic adults: an open pilot study in a psychiatric outpatient context., J. Contextual. Behav. Sci., 13, p. 34, DOI: 10.1016/j.jcbs.2019.04.002 55 10.1016/j.jcbs.2019.04.002 false true Reference 51049233 /api/reference/51049233 56. Philipsen 2012: Psychotherapy in adult attention deficit hyperactivity disorder: implications for treatment and research., Expert Rev. Neurother., 12, p. 1217, DOI: 10.1586/ern.12.91 56 10.1586/ern.12.91 false true Reference 51049234 /api/reference/51049234 57. Philipsen 2015: Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial., JAMA Psychiatry, 72, p. 1199, DOI: 10.1001/jamapsychiatry.2015.2146 57 10.1001/jamapsychiatry.2015.2146 false true Reference 51049235 /api/reference/51049235 58. Philipsen 2007: Structured group psychotherapy in adults with attention deficit hyperactivity disorder: results of an open multicentre study., J. Nerv. Ment. Dis., 195, p. 1013, DOI: 10.1097/NMD.0b013e31815c088b 58 10.1097/NMD.0b013e31815c088b false true Reference 51049236 /api/reference/51049236 59. Pliszka 2022: A review of clinical practice guidelines in the diagnosis and treatment of attention-deficit/hyperactivity disorder., Child Adolesc. Psychiatr. Clin. N. Am., 31, p. 569, DOI: 10.1016/j.chc.2022.03.009 59 10.1016/j.chc.2022.03.009 false true Reference 51049237 /api/reference/51049237 60. Poissant 2019: Behavioral and cognitive impacts of mindfulness-based interventions on adults with attention-deficit hyperactivity disorder: a systematic review., Behav. Neurol., 2019, DOI: 10.1155/2019/5682050 60 10.1155/2019/5682050 false true Reference 51049238 /api/reference/51049238 61. Posner 2020: Attention-deficit hyperactivity disorder., Lancet, 395, p. 450, DOI: 10.1016/S0140-6736(19)33004-1 61 10.1016/S0140-6736(19)33004-1 false true Reference 51049239 /api/reference/51049239 62. Powell 2022: Psychoeducation intervention effectiveness to improve social skills in young people with ADHD: a meta-analysis., J. Atten. Disord., 26, p. 340, DOI: 10.1177/1087054721997553 62 10.1177/1087054721997553 false true Reference 51049240 /api/reference/51049240 63. Price 2023: Extended-release viloxazine compared with atomoxetine for attention deficit hyperactivity disorder., CNS Drugs, 37, p. 655, DOI: 10.1007/s40263-023-01023-6 63 10.1007/s40263-023-01023-6 false true Reference 51049241 /api/reference/51049241 64. Radonjić 2023: Nonstimulant medications for attention-deficit/hyperactivity disorder (ADHD) in adults: systematic review and meta-analysis., CNS Drugs, 37, p. 381, DOI: 10.1007/s40263-023-01005-8 64 10.1007/s40263-023-01005-8 false true Reference 51049242 /api/reference/51049242 65. Ramsay 2010: CBT for adult ADHD: adaptations and hypothesized mechanisms of change., J. Cogn. Psychother., 24, p. 37, DOI: 10.1891/0889-8391.24.1.37 65 10.1891/0889-8391.24.1.37 false true Reference 51049243 /api/reference/51049243 66. Ramsay 2020: Rethinking Adult ADHD: Helping clients Turn Intentions Into Actions 66 false true Reference 51049244 /api/reference/51049244 67. Russell 2023: Complementary and integrative treatments for attention-deficit/hyperactivity disorder in youth., Child Adolesc. Psychiatr. Clin. N. Am., 32, p. 173, DOI: 10.1016/j.chc.2022.08.005 67 10.1016/j.chc.2022.08.005 false true Reference 51049245 /api/reference/51049245 68. Sagvolden 2005: A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes., Behav. Brain Sci., 28, p. 397, DOI: 10.1017/S0140525X05000075 68 10.1017/S0140525X05000075 false true Reference 51049246 /api/reference/51049246 69. Sayal 2018: ADHD in children and young people: prevalence, care pathways, and service provision., Lancet Psychiatry, 5, p. 175, DOI: 10.1016/S2215-0366(17)30167-0 69 10.1016/S2215-0366(17)30167-0 false true Reference 51049247 /api/reference/51049247 70. Selaskowski 2022: Smartphone-assisted psychoeducation in adult attention-deficit/hyperactivity disorder: a randomized controlled trial., Psychiatry Res., 317, DOI: 10.1016/j.psychres.2022.114802 70 10.1016/j.psychres.2022.114802 false true Reference 51049248 /api/reference/51049248 71. Sergeant 2000: The cognitive-energetic model: an empirical approach to attention-deficit hyperactivity disorder., Neurosci. Biobehav. Rev., 24, p. 7, DOI: 10.1016/S0149-7634(99)00060-3 71 10.1016/S0149-7634(99)00060-3 false true Reference 51049249 /api/reference/51049249 72. Shaw 2012: A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment., BMC Med., 10, p. 1, DOI: 10.1186/1741-7015-10-99 72 10.1186/1741-7015-10-99 false true Reference 51049250 /api/reference/51049250 73. Shrestha 2020: Non-pharmacologic management of attention-deficit/hyperactivity disorder in children and adolescents: a review., Transl. Pediatr., 9, p. S114, DOI: 10.21037/tp.2019.10.01 73 10.21037/tp.2019.10.01 false true Reference 51049251 /api/reference/51049251 74. Sibley 2023: Non-pharmacological interventions for attention-deficit hyperactivity disorder in children and adolescents., Lancet Child Adolesc. Health, DOI: 10.1016/S2352-4642(22)00381-9 74 10.1016/S2352-4642(22)00381-9 false true Reference 51049252 /api/reference/51049252 75. Sibley 2016: Parent–teen behavior therapy+ motivational interviewing for adolescents with ADHD., J. Consult. Clin. Psychol., 84, p. 699, DOI: 10.1037/ccp0000106 75 10.1037/ccp0000106 false true Reference 51049253 /api/reference/51049253 76. Sibley 2013: A pilot trial of Supporting Teens’ Academic Needs Daily (STAND): a parent-adolescent collaborative intervention for ADHD., J. Psychopathol. Behav. Assess., 35, p. 436, DOI: 10.1007/s10862-013-9353-6 76 10.1007/s10862-013-9353-6 false true Reference 51049254 /api/reference/51049254 77. Sibley 2017: Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity., J. Child Psychol. Psychiatry, 58, p. 655, DOI: 10.1111/jcpp.12620 77 10.1111/jcpp.12620 false true Reference 51049255 /api/reference/51049255 78. Sonuga-Barke 2002: Psychological heterogeneity in AD/HD—A dual pathway model of behaviour and cognition., Behav. Brain Res., 130, p. 29, DOI: 10.1016/S0166-4328(01)00432-6 78 10.1016/S0166-4328(01)00432-6 false true Reference 51049256 /api/reference/51049256 79. Spaniardi 2017: Attention-deficit/hyperactivity disorder.Kaplan & Sadock's Comprehensive Textbook of Psychiatry 79 false true Reference 51049257 /api/reference/51049257 80. Sprich 2016: A randomized controlled trial of cognitive behavioral therapy for ADHD in medication-treated adolescents., J. Child Psychol. Psychiatry, 57, p. 1218, DOI: 10.1111/jcpp.12549 80 10.1111/jcpp.12549 false true Reference 51049258 /api/reference/51049258 81. Stahl 2021: Stahl's Essential Psychopharmacology Neuroscientific Basis and Practical Applications 81 false true Reference 51049259 /api/reference/51049259 82. Storebø 2019: Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years., Cochrane Database Syst. Rev., DOI: 10.1002/14651858.CD008223.pub3 82 10.1002/14651858.CD008223.pub3 false true Reference 51049260 /api/reference/51049260 83. Sullivan 2022: Examining the pharmacological and psychological treatment of child and adolescent ADHD in Australia: protocol for a retrospective cohort study using linked national registry data., BMJ Open, 12, DOI: 10.1136/bmjopen-2022-064920 83 10.1136/bmjopen-2022-064920 false true Reference 51049261 /api/reference/51049261 84. Thorell 2022: Longitudinal associations between digital media use and ADHD symptoms in children and adolescents: a systematic literature review., Eur. Child Adolesc. Psychiatry, p. 1 84 false true Reference 51049262 /api/reference/51049262 85. Tourjman 2022: Psychosocial interventions for attention deficit/hyperactivity disorder: a systematic review and meta-analysis by the CADDRA guidelines Work GROUP., Brain Sci., 12, DOI: 10.3390/brainsci12081023 85 10.3390/brainsci12081023 false true Reference 51049263 /api/reference/51049263 86. Vaag 2019: Psychoeducational groups versus waitlist in treatment of attention-deficit hyperactivity/impulsivity disorder (ADHD) in adults: a protocol for a pilot randomized waitlist-controlled multicenter trial., Pilot. Feasibility Stud., 5, p. 1, DOI: 10.1186/s40814-019-0401-1 86 10.1186/s40814-019-0401-1 false true Reference 51049264 /api/reference/51049264 87. Van Vyve 2023: Pharmacotherapy for ADHD in children and adolescents: a summary and overview of different European guidelines., Eur. J. Pediatr., DOI: 10.1007/s00431-023-05370-w 87 10.1007/s00431-023-05370-w false true Reference 51049265 /api/reference/51049265 88. Vekety 2021: The effect of mindfulness-based interventions on inattentive and hyperactive–impulsive behavior in childhood: a meta-analysis., Int. J. Behav. Dev., 45, p. 133, DOI: 10.1177/0165025420958192 88 10.1177/0165025420958192 false true Reference 51049266 /api/reference/51049266 89. Vidal 2013: Psychoeducation for adults with attention deficit hyperactivity disorder vs. cognitive behavioral group therapy: a randomized controlled pilot study., J. Nerv. Ment. Dis., 201, p. 894, DOI: 10.1097/NMD.0b013e3182a5c2c5 89 10.1097/NMD.0b013e3182a5c2c5 false true Reference 51049267 /api/reference/51049267 90. Watson 2015: Psychosocial treatments for ADHD: a systematic appraisal of the evidence., J. Atten. Disord., 19, p. 3, DOI: 10.1177/1087054712447857 90 10.1177/1087054712447857 false true Reference 51049268 /api/reference/51049268 91. Wolraich 2019: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents., Pediatrics., 144, DOI: 10.1542/peds.2019-2528 91 10.1542/peds.2019-2528 false true Reference 51049269 /api/reference/51049269 92. Wu 2022: Complementary and alternative medicine use by ADHD patients: a systematic review., J. Atten. Disord., 26, p. 1833, DOI: 10.1177/10870547221111557 92 10.1177/10870547221111557 false true Reference 51049270 /api/reference/51049270 93. Yankura 1997: Using REBT with Common Psychological Problems: A Therapist's Casebook 93 false true Reference 51049271 /api/reference/51049271 94. Young 2016: Adult attention-deficit/hyperactivity disorder diagnosis, management, and treatment in the DSM-5 Era., Prim. Care Companion CNS Disord., 18 94 false true Reference 51049272 /api/reference/51049272 95. Young 2012: Cognitive-Behavioural Therapy For ADHD in Adolescents and Adults: A psychological Guide to Practice 95 false true Reference 51049273 /api/reference/51049273 96. Young 2020: The efficacy of cognitive behavioral therapy for adults with ADHD: a systematic review and meta-analysis of randomized controlled trials., J. Atten. Disord., 24, p. 875, DOI: 10.1177/1087054716664413 96 10.1177/1087054716664413 false true Reference 51049274 /api/reference/51049274 97. Zwi 2011: Parent training interventions for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years., Cochrane Database Syst. Rev., DOI: 10.1002/14651858.CD003018.pub3 97 10.1002/14651858.CD003018.pub3 false true /api/publication/34740343 Gonda Xenia et al. Settling a distracted globe: An overview of psychosocial and psychotherapeutic treatment of attention-deficit/hyperactivity disorder. (2024) EUROPEAN NEUROPSYCHOPHARMACOLOGY 0924-977X 1873-7862 83 1-8<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10003491"><a href="/gui2/?type=authors&mode=browse&sel=10003491" target="_blank">Gonda Xenia ✉ (<span class="authorship-author-name">Gonda Xénia</span> <span class="authorAux-mtmt"> Pszichiátria, pszichiátriai genetika, farmakoló...</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pszichiátriai és Pszichoterápiás Klinika; <span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/<span title="Gyógyszerhatástani Intézet">GYHATAS</span>/NAP3.0-SE Neuropszichofarmakológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10043365"><a href="/gui2/?type=authors&mode=browse&sel=10043365" target="_blank">Balint Sara (<span class="authorship-author-name">Bálint Sára</span> <span class="authorAux-mtmt"> Pszichiátria</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pszichiátriai és Pszichoterápiás Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10021998"><a href="/gui2/?type=authors&mode=browse&sel=10021998" target="_blank">Rethelyi Janos Miklos (<span class="authorship-author-name">Réthelyi János</span> <span class="authorAux-mtmt"> Pszichiátria- kognítiv idegtudomány</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pszichiátriai és Pszichoterápiás Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023468"><a href="/gui2/?type=authors&mode=browse&sel=10023468" target="_blank">Dome Peter (<span class="authorship-author-name">Döme Péter</span> <span class="authorAux-mtmt"> pszichiátria</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pszichiátriai és Pszichoterápiás Klinika</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34740343" target="_blank">Settling a distracted globe: An overview of psychosocial and psychotherapeutic treatment of attention-deficit/hyperactivity disorder</a></div> <div> <span class="journal-title">EUROPEAN NEUROPSYCHOPHARMACOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0924-977X">0924-977X</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1873-7862">1873-7862</a>)</span>: <span class="journal-volume">83</span> <span class="page"> pp 1-8 </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1016/j.euroneuro.2024.03.002" target="_blank" href="https://doi.org/10.1016/j.euroneuro.2024.03.002"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001225869700001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001225869700001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85188087977" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85188087977"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38490015" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38490015&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Neurology (clinical)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Neurology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology (medical)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Psychiatry and Mental Health&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biological Psychiatry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 4</span> | Független: 4 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 4 | Scopus jelölt:&nbsp;3 | WoS/Scopus jelölt:&nbsp;4 | DOI jelölt:&nbsp;4 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34740343&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 2 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34740343</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="lastModified">Utolsó módosítás: 2024.06.07. 11:41 Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) </div> </div></div>